Reported Dec 16, 2020 · Terminated

Azacitidine for Injection 100 mg/vial, For Subcutaneous and Intravenous Use Only, Rx Only, One Single Dose Vial,…

Shilpa Medicare Limited

Moderate riskThis product could cause temporary or reversible health problems — stop using it.

What you should do

Stop using the affected lot and contact the recalling firm for the return or refund process. Check the FDA enforcement report for lot-level detail.

Firm contact: Shilpa Medicare Limited · S-20 To S-26, Pharm. Formulation Sez · Polepally, Jadcherla, N/A · N/A

Is this the product you have?

  • Azacitidine for Injection 100 mg/vial, For Subcutaneous and Intravenous Use Only, Rx Only, One Single Dose Vial, Cytotoxic Agent
  • Manufactured byShilpa Medicare Limited, India
  • Distributed byArmas Pharmaceuticals, Inc., Manalapan, NJ 07726, NDC 72606-558-01
Lot codes and dates
    • Lot #: 7S10227A
    • Exp. 10/31/2021
Amount recalled
6,560 vials

This recall covers 6 products

The agency filed one notice per product. You are reading one of them; the other 5 are below.

Where it was sold

  • Nationwide

Why it was recalled

CGMP Deviations

This product could cause temporary or reversible health problems — stop using it.

Want the full recall guide?

The guide adds the identifying codes laid out for scanning, symptoms to watch for, a timeline, and news coverage of this recall.

Free recall alerts

Get alerted about new Shilpa Medicare Limited recalls

One email when a matching recall is published. No account, no cost, unsubscribe in one click.

Where this came from

Source: U.S. Food & Drug Administration (openFDA)

Read the FDA (openFDA drug enforcement) notice

Notice updated Mar 11, 2022 · Data as of Sep 19, 4:18 PM UTC

RecallNow is not a government agency. Every fact on this page is published by the FDA, USDA or CPSC and links back to their notice.